What is Phagenyx?
Phagenyx specializes in the development of the Phagenyx System, a sophisticated neurostimulation device engineered to address swallowing safety and efficiency in patients suffering from post-stroke dysphagia. By utilizing targeted pharyngeal electrical stimulation, the system facilitates the restoration of neural control over the swallowing mechanism, thereby accelerating patient recovery and optimizing clinical workflows. The company operates at the intersection of medical device innovation and evidence-based healthcare, providing a critical solution for healthcare providers tasked with managing complex dysphagia cases in acute and post-acute settings.
How much funding has Phagenyx raised?
Phagenyx has raised a total of $62.5M across 4 funding rounds:
Series A
$2.3M
Grant
$1.1M
Series B
$17M
Series D
$42M
Series A (2010): $2.3M with participation from Undisclosed
Grant (2012): $1.2M led by Wellcome Trust
Series B (2013): $17M supported by Inventages
Series D (2024): $42M featuring Sectoral Asset Management, British Patient Capital, EQT, and Northern Gritstone
Key Investors in Phagenyx
Sectoral Asset Management
An investment advisor specializing in managing equities globally within the healthcare sector, with a strong track record in biotech and private equity healthcare strategies.
British Patient Capital
A government-owned economic entity focused on providing equity finance and support to innovative UK businesses to drive growth and improve finance markets.
EQT
A global private-capital investment platform that applies a thematic, sector-focused approach to healthcare and technology, supporting companies across various development stages.
What's next for Phagenyx?
With the successful closure of this major enterprise-level funding, Phagenyx is poised to scale its commercial operations and expand its clinical evidence base. The strategic focus will likely shift toward broader market penetration and the integration of its neurostimulation platform into standard care protocols across international healthcare systems. As the company transitions into this next phase of maturity, the emphasis will remain on demonstrating long-term value to both clinical stakeholders and the broader healthcare ecosystem, ensuring that its technology remains at the forefront of dysphagia management and patient-centric care.
See full Phagenyx company page
